Samsung BioLogics, Ichnos Sciences eye W20tr atopic dermatitis market
Nov 5, 2019
Samsung BioLogics and US’ Ichnos Sciences inked a long-term agreement for the latter’s contract development of an atopic dermatitis treatment, the companies said Tuesday. This is a continuation of the 10 billion-won ($8.61 million) contract inked between the two in June 2018. For an additional 6.3 billion won, BioLogics will produce the drug substance for Ichnos’ atopic dermatitis treatment pipeline ISB 830 for clinical phase 3 trials and potentially manufacture for the global